Freenome Reports Third Quarter 2026 Financial Results

Freenome reported third-quarter 2026 revenue of $183.5 million, up from $1.0 million a year earlier, including $180.0 million recognized under a collaboration and license agreement after FDA approval of its SimpleScreen CRC test. The company ended the quarter with $430.0 million in cash, cash equivalents, and marketable securities. Freenome forecast full-year 2026 revenue of $192 million to $194 million, including contributions from licensing and collaboration agreements, R&D services, and early commercial activity.